CN106282326A - Screening or detecting method for allergic rhinitis - Google Patents
Screening or detecting method for allergic rhinitis Download PDFInfo
- Publication number
- CN106282326A CN106282326A CN201510312327.7A CN201510312327A CN106282326A CN 106282326 A CN106282326 A CN 106282326A CN 201510312327 A CN201510312327 A CN 201510312327A CN 106282326 A CN106282326 A CN 106282326A
- Authority
- CN
- China
- Prior art keywords
- tap1
- codon
- allergic rhinitis
- allele
- screening
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010039085 Rhinitis allergic Diseases 0.000 title claims abstract description 49
- 201000010105 allergic rhinitis Diseases 0.000 title claims abstract description 49
- 238000012216 screening Methods 0.000 title claims abstract description 32
- 238000000034 method Methods 0.000 title claims abstract description 28
- 108020004705 Codon Proteins 0.000 claims abstract description 66
- 108700028369 Alleles Proteins 0.000 claims abstract description 48
- 108010023335 Member 2 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims abstract description 45
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 43
- 150000001413 amino acids Chemical group 0.000 claims abstract description 31
- 239000004471 Glycine Substances 0.000 claims abstract description 21
- 238000001514 detection method Methods 0.000 claims abstract description 14
- 102000002156 Antigen peptide transporter 1 Human genes 0.000 claims abstract 3
- 102100030346 Antigen peptide transporter 1 Human genes 0.000 claims description 42
- 229940024606 amino acid Drugs 0.000 claims description 30
- 235000001014 amino acid Nutrition 0.000 claims description 30
- 238000013098 chemical test method Methods 0.000 claims description 26
- 206010039083 rhinitis Diseases 0.000 claims description 21
- 238000005259 measurement Methods 0.000 claims description 15
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 14
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 14
- 210000004369 blood Anatomy 0.000 claims description 14
- 239000008280 blood Substances 0.000 claims description 14
- 239000004474 valine Substances 0.000 claims description 14
- 108010078791 Carrier Proteins Proteins 0.000 claims description 11
- 239000000427 antigen Substances 0.000 claims description 11
- 108091007433 antigens Proteins 0.000 claims description 11
- 102000036639 antigens Human genes 0.000 claims description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- 102000014914 Carrier Proteins Human genes 0.000 claims description 8
- 210000002381 plasma Anatomy 0.000 claims description 6
- 238000012360 testing method Methods 0.000 claims description 5
- 210000003491 skin Anatomy 0.000 claims description 4
- 230000004069 differentiation Effects 0.000 claims description 3
- 210000004905 finger nail Anatomy 0.000 claims description 3
- 210000004209 hair Anatomy 0.000 claims description 3
- 210000003296 saliva Anatomy 0.000 claims description 3
- 210000002700 urine Anatomy 0.000 claims description 3
- XDDMZVMWZMSAMX-JHNJPSDUSA-N (2s,3s)-2-azanyl-3-methyl-pentanoic acid Chemical compound CC[C@H](C)[C@H](N)C(O)=O.CC[C@H](C)[C@H](N)C(O)=O XDDMZVMWZMSAMX-JHNJPSDUSA-N 0.000 claims 2
- GICLSALZHXCILJ-UHFFFAOYSA-N ctk5a5089 Chemical compound NCC(O)=O.NCC(O)=O GICLSALZHXCILJ-UHFFFAOYSA-N 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 abstract description 5
- AWNBSWDIOCXWJW-WTOYTKOKSA-N (2r)-n-[(2s)-1-[[(2s)-1-(2-aminoethylamino)-1-oxopropan-2-yl]amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]-n'-hydroxy-2-(2-methylpropyl)butanediamide Chemical compound C1=CC=CC2=CC(C[C@H](NC(=O)[C@@H](CC(=O)NO)CC(C)C)C(=O)N[C@@H](C)C(=O)NCCN)=CC=C21 AWNBSWDIOCXWJW-WTOYTKOKSA-N 0.000 abstract 1
- 102000011202 Member 2 Subfamily B ATP Binding Cassette Transporter Human genes 0.000 abstract 1
- 230000009977 dual effect Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 description 13
- 238000001962 electrophoresis Methods 0.000 description 10
- 230000009182 swimming Effects 0.000 description 10
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 9
- 229960000310 isoleucine Drugs 0.000 description 9
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 8
- 238000003752 polymerase chain reaction Methods 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000035772 mutation Effects 0.000 description 5
- 102100030343 Antigen peptide transporter 2 Human genes 0.000 description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 208000036071 Rhinorrhea Diseases 0.000 description 4
- 206010039101 Rhinorrhoea Diseases 0.000 description 4
- 235000003704 aspartic acid Nutrition 0.000 description 4
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 4
- 101150080773 tap-1 gene Proteins 0.000 description 4
- 206010028748 Nasal obstruction Diseases 0.000 description 3
- 101800000849 Tachykinin-associated peptide 2 Proteins 0.000 description 3
- 239000013566 allergen Substances 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 239000000428 dust Substances 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 241001428166 Eucheuma Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 229960004784 allergens Drugs 0.000 description 2
- 238000000546 chi-square test Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 244000187656 Eucalyptus cornuta Species 0.000 description 1
- -1 Gly-636 phenogen) Chemical compound 0.000 description 1
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108010023338 Member 3 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000001705 Mouth breathing Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 101710176384 Peptide 1 Proteins 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010041235 Snoring Diseases 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 101150011263 Tap2 gene Proteins 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 244000144992 flock Species 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108010082406 peptide permease Proteins 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 239000002342 ribonucleoside Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- QQJLHRRUATVHED-UHFFFAOYSA-N tramazoline Chemical compound N1CCN=C1NC1=CC=CC2=C1CCCC2 QQJLHRRUATVHED-UHFFFAOYSA-N 0.000 description 1
- 229960001262 tramazoline Drugs 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 229940046536 tree pollen allergenic extract Drugs 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
A method for screening a high risk group for allergic rhinitis in vitro comprising: (1) providing a sample for detecting a codon (codon) for translating an amino acid at position 637 (TAP1-637) in a allele of antigen peptide transporter 1 (TAP 1) in the sample of a subject, wherein the subject is a human; and (2) judging the detection result in the step (1), and if the detection result in the step (1) shows that the codons of the two TAP1-637 of the dual gene sequence all correspond to glycine (glycine), determining that the screened individual is a high risk group of allergic rhinitis.
Description
Technical field
The highrisk populations that present disclosure generally relates to allergic rhinitis in a kind of screening Chinese or the method distinguishing rhinitis type, especially with respect to via measuring antigen victory peptide transport protein matter 1 (antigen peptide transporter 1, TAP1) allele is translated the codon of the aminoacid (TAP1-637) of the 637th position, with highrisk populations or the method for differentiation rhinitis type of screening allergic rhinitis in Chinese.
Background technology
Allergic rhinitis (allergic rhinitis) refers to the people of allergic constitution, for some anaphylactogens in the middle of environment, such as dust, mycete, pollen, dust mite, the soft flocks of animal, specific food, or the existing picture of the allergy that the factor tetchiness such as climate change, air pollution is caused, the most relevant with the heredity of familial.The classical symptom of allergic rhinitis includes that sneeze, nose are itched, runny nose, nasal obstruction, eyes are itched, throat is itched, chronic cough, mouth breathing, snoring at night etc., foregoing conditions occurs for a long time, sufferer may be further resulted in the symptoms such as dizziness, headache, not good, the insomnia of spirit occur, have a strong impact on the quality of the life of sufferer.
At present clinically for the diagnostic method of allergic rhinitis, mainly according to sufferer persistence, typical allergic rhinitis symptoms occurs, it is aided with Blood routine examination again, such as check IgE (IgE) and/or eosnophilia leukocyte (eosinophils) concentration in blood, if persistently there is typical allergic rhinitis symptoms in sufferer, and the concentration of IgE and/or eosnophilia leukocyte raises in blood, then it represents that patient probably has been inflicted with allergic rhinitis.But, the diagnostic method of aforementioned conventional, just cannot diagnose before easily suffering from the morbidity of allergic rhinitis, therefore, the highrisk populations of allergic rhinitis are (such as, the probability person of being greatly improved suffering from allergic rhinitis is caused because of Inheritance) the most first cannot make a definite diagnosis before morbidity, therefore have no way of preventing ahead of time to suffer from allergic rhinitis.
Antigen victory peptide transport protein matter (antigen peptide transporter, it is called for short " TAP ") it is that antigen wins peptide transport protein matter 1 (antigen peptide transporter1, or referred to as transporter antigen peptide 1, it is called for short " TAP1 ") win peptide transport protein matter 2 (antigen peptide transporter 2 with antigen, or referred to as transporter antigen peptide 2, it is called for short " TAP2 ") heterodimeric proteins that formed, respectively by TAP1 gene and TAP2 coded by said gene.Victory peptide can be transported in endoplasmic reticulum by TAP by Cytoplasm.
TAP1 and TAP2 respectively has a hydrophobicity transmembrane domains territory (domain) and an ATP-calmodulin binding domain CaM (ATP-binding domain).Previously studied discovery, the gene pleiomorphism (polymorphisms) of TAP1 gene and TAP2 gene includes the aminoacid (being positioned at hydrophobicity transmembrane domains territory) of No. 333 position, and the aminoacid (being positioned at ATP-calmodulin binding domain CaM) of No. 637 position, wherein, the amino acid whose variation of No. 333 position of TAP and/or No. 637 position may change the specificity of substrate and the function of TAP.Research display, to suffer from the Japanese of allergic rhinitis as research individuality, there is no relatedness between polymorphism and the allergic rhinitis of TAP1 and (see the document of Takeuchi K et al., Lack of association between gene polymorphism of transporters associated with antigen processing and allergic rhinitis in a Japanese population.Ann Otol Rhinol Laryngol.2002；111:460 463, the document is in full and in the most for reference).
But, have been surprisingly found that after inventor's research, for Chinese, then and there is the relatedness of height in the polymorphism of the codon (codon) translating the codon of the aminoacid (TAP1-637) of the 637th position and the aminoacid (TAP1-333) of the 333rd position in the allele of TAP1 between allergic rhinitis.Therefore.Can pass through the allele of TAP1 is translated the detection of the codon (codon) of the aminoacid (TAP1-333) of the codon of the aminoacid (TAP1-637) of the 637th position and the 333rd position, come the highrisk populations of allergic rhinitis in screening Chinese and/or distinguish rhinitis type.
Summary of the invention
One purpose of the present invention, the method being to provide the highrisk populations of a kind of external screening allergic rhinitis, including: (1) detection one is by antigen victory peptide transport protein matter 1 (antigen peptide transporter 1 in a corpse or other object for laboratory examination and chemical testing for screening individuality, TAP1) allele is translated the codon of the aminoacid (TAP1-637) of the 637th position, wherein should be by the individual Chinese of screening；And (2) judge the measurement result of step (1), when the measurement result of step (1) shows all corresponding glycine (glycine of codon of two TAP1-637 of this allele sequence, Gly), then should be the highrisk populations of allergic rhinitis by screening individuality.
Another object of the present invention, it is to provide a kind of method distinguishing rhinitis type, including: translating the codon of the aminoacid (TAP1-637) of the 637th position in a corpse or other object for laboratory examination and chemical testing for (1) detection one examined individuality in the allele of antigen victory peptide transport protein matter 1, wherein this individuality is a Chinese suffering from rhinitis；And (2) judge the measurement result of step (1), when the measurement result of step (1) shows all corresponding glycine of codon of two TAP1-637 of this allele sequence, and the most described rhinitis is allergic rhinitis.
Detailed technology content and the part of the present invention are embodied as aspect, will be described in herein below, have usual skill for art of the present invention and understand the feature of the present invention according to this.
Accompanying drawing explanation
1st figure show the electrophoretogram carrying out electrophoretic analysis after genomic DNA carries out ARMS-PCR, and wherein, swimming lane " M " is electrophoretic labels (marker)；Swimming lane 1 is the shaped body of Val-333 and Ile-333；Swimming lane 2 is the phenogen of Ile-333；Swimming lane 3 is the shaped body of Asp-637 and Gly-636；Swimming lane 4 is the phenogen of Asp-637.
Detailed description of the invention
Part according to the present invention explained below is embodied as aspect；But, without departing substantially under spirit of the present invention, the present invention still can aspect in many different forms put into practice, and scope should not be considered limited to description institute representor.Additionally, unless Wen Zhongyou additionally illustrates, (the most in the claims) used it " one ", " being somebody's turn to do " and similar term to be interpreted as comprising odd number and plural form in this specification.
Inventor finds, the polymorphism of TAP1-637 is relevant with the allergic rhinitis of Chinese, if one by all corresponding glycine (Gly-637) of codon of two TAP1-637 of the individual allele sequence of screening, should be then the highrisk populations of allergic rhinitis by screening individuality, if and this Chinese itself be patients with rhinitis (such as, the symptom of rhinitis has occurred), then this rhinitis is allergic rhinitis.
Therefore, the present invention provides the method for the highrisk populations of a kind of external screening allergic rhinitis, described method includes: (1) detection one, by the codon of the aminoacid (TAP1-637) translating the 637th position in the allele of TAP1 in this corpse or other object for laboratory examination and chemical testing of screening individuality, should be wherein a Chinese by screening individuality；And (2) judge the measurement result of step (1), when the measurement result of step (1) shows all corresponding glycine of codon of two TAP1-637 of this allele sequence, then should be the highrisk populations of allergic rhinitis by screening individuality.
In the present invention, so-called " Chinese " refers to the group with Chinese blood lineage, including such as, and China's Mainland and TaiWan, China people.In the part according to the present invention implements aspect, it is artificially individual by screening with TaiWan, China.
The corpse or other object for laboratory examination and chemical testing being suitable for the inventive method step (1) there is no particular restriction, as long as this corpse or other object for laboratory examination and chemical testing comprises the genomic DNA (genomic DNA) by screening individuality.For example, this corpse or other object for laboratory examination and chemical testing can be selected from following at least one: blood, blood plasma, urine, saliva, fingernail, skin and hair, and preferably blood and at least one of blood plasma.Additionally, the consumption of this corpse or other object for laboratory examination and chemical testing is also without particular restriction, as long as required bio information can be provided.
In the step (1) of the inventive method, any suitable method can be used to the amino acid whose codon of translation the 637th position in the allele measure TAP1.nullFor example，Can carry out selected from following at least one in step (1): polymerase chain reaction (polymerase chain reaction)、Amplification refractory mutation system polymerase chain reaction (amplification-refractory mutation system polymerase chain reaction，ARMS-PCR)、Polymerase chain reaction-restriction enzyme fragment length pleiomorphism analyzes (polymerase chain reaction-restriction fragment length polymorphism analysis，PCR-RFLP)、And marking hybridization (southern blot) analysis.As shown in rear attached embodiment, implement in aspect in the part according to the present invention, use the specific primers for TAP1-637 to carry out ARMS-PCR, to analyze a described corpse or other object for laboratory examination and chemical testing, follow-up carry out the Eucheuma gelatinosum gel electrophoresis analysis nucleic acid product through ARMS-PCR amplification again.
In the step (2) of the inventive method, the measurement result utilizing step (1) judge by screening individual be whether the highrisk populations of allergic rhinitis, wherein, when the measurement result of step (1) shows all corresponding glycine of codon of two TAP1-637 of TAP1 allele (i.e., should be by screening individuality for belonging to Asp-637 phenogen (homozygous)) time, then should be the highrisk populations of allergic rhinitis by screening individuality.
In the inventive method, in addition to the allele of TAP1 in a detection corpse or other object for laboratory examination and chemical testing is translated the amino acid whose codon of the 637th position, the step of the amino acid whose codon translating the 333rd position in a corpse or other object for laboratory examination and chemical testing in the allele of TAP1 can be detected further, to improve the accuracy rate of screening.For example, the step of the amino acid whose codon translating the 333rd position in the allele sequence of this TAP1 of mensuration can be further included in the step (1) of the present invention, when measurement result shows all corresponding glycine of codon of two TAP1-637 of this allele sequence, and the codon of this two TAP1-333 each corresponding valine or isoleucine are (i.e., the all corresponding valine of the codon of two TAP1-333, the all corresponding isoleucine of the codon of two TAP1-333, or the wherein password subsystem correspondence valine of a TAP1-333, the password subsystem correspondence isoleucine of another TAP1-333), should be then the highrisk populations of allergic rhinitis by screening individuality.
According to the inventive method, if itself Rhinitis Symptoms having been occurred (such as by screening individuality, sneeze, nose are itched, runny nose, nasal obstruction etc.) and/or be diagnosed as suffering from rhinitis through Blood routine examination, then may utilize the aforementioned screening methods of the present invention, to distinguish this rhinitis type.Therefore, the present invention also provides a kind of method of external differentiation rhinitis type, including: (1) detects a corpse or other object for laboratory examination and chemical testing for an individuality, measures the codon translating TAP1-637 in the allele of TAP1, and wherein this individuality is a Chinese suffering from rhinitis；And (2) judge the measurement result of step (1), when the measurement result of step (1) shows all corresponding glycine of codon of two TAP1-637 of this allele sequence, and the most described rhinitis is allergic rhinitis.Wherein, about selection, corpse or other object for laboratory examination and chemical testing kind and the acquisition mode of this individuality and the allele of mensuration TAP1 are translated method and the preferably enforcement aspect etc. of the codon of TAP1-637, the most as the above description, and this differentiating method also can farther include to measure described above the step of the amino acid whose codon translating the 333rd position in the allele sequence of TAP1.
The present invention is hereby illustrated further with the following example.The most such embodiment is merely provided as explanation, and is not used to limit the scope of the invention.Shown in scope claim.
Embodiment: the analysis of TAP1 gene pleiomorphism
The most tested individuality
The tested individuality that the present embodiment is used comprises 160 TaiWan, China people, wherein 73 is the patient suffering from allergic rhinitis after diagnosing, remaining 87 is healthy individuals, all tested individualities are all by justice large hospital (Gaoxiong City, TaiWan, China) clinic call together, and carry out following experiment through tested individual agreement.Described 73 is to make a definite diagnosis based on one or more diagnostic criteria following for suffering from the diagnostic mode of the patient of allergic rhinitis after diagnosing: the clinical symptoms such as (1) sneeze, watery rhinorrhea (watery rhinorrhea) and nasal obstruction；(2) family history of anaphylactic disease；(3) the total IgE concentration raised in serum, acidophilia's ball increase disease (eosinophilia) of nasal smear (nasal smears)；(4) skin test is positive for one or more general inhalant allergens, including dust mite, flowers and plants mixture (grass mix), cat anaphylactogen (cat allergen) and tree pollen mixture；And (5) excite positive test for one or more general inhalant allergens.All healthy individuals (that is, as the individuality of control group) all related symptoms for aforementioned allergic rhinitis are negative with examination criteria.Sex and the mean age of 160 tested individualities are as shown in table 1 below.
Table 1
B. blood sample is collected
The blood sample of 20 milliliters of above-mentioned 160 tested individualities of extraction is to vacuum test tube (the BD Biosciences being added with heparin respectively, New Jersey, the U.S.), exist side by side and i.e. use QIAamp DNA Blood Mini set group (Qiagen company, California, the U.S.), operation instruction according to set group carries out the extraction of genomic DNA, afterwards, genomic DNA sample is stored in-80 DEG C, uses for the experiment of following analysis of molecules.
C. amplification refractory mutation system polymerase chain reaction
Use amplification refractory mutation system polymerase chain reaction (amplification-refractory mutation system polymerase chain reaction, ARMS-PCR) the genomic DNA sample that above-mentioned B is obtained is analyzed, to analyze the TAP1 gene aminoacid in No. 637 position and the amino acid whose polymorphism of No. 333 position.First, preparation PCR reactant mixture, add 1 milligram of genosome DNA, 0.2 millimolar concentration deoxyribose ribonucleoside triphosphote (deoxynucleotide triphosphates, dNTP), 0.25 microgram oligonucleotide introduction (totally 4 kinds), 2 units (unit) archaeal dna polymerase (Stratagene, California, the U.S.), and add 1 times of reaction buffer to volume 100 microlitre.Wherein, adding to 4 kinds of oligonucleotide introductions in this PCR reactant mixture, two of which (respectively underlying stock and anti-stock) oligonucleotide is designed so that its 3 ' terminal nucleotide can the one of which of two kinds of variants of amino acid whose TAP1 nucleotide of the complementary aminoacid to No. 333 positions of coding or No. 637 positions.Other two kinds (respectively underlying stock and anti-stock) oligonucleotide are designed to the both wings sequence (flanking sequences) of the asymmetry-distance making its complementation to the either side of the nucleotide being positioned at polymorphism, for detecting the sequence system of the introduction of the amino acid whose polymorphism of aminoacid or No. 637 positions encoding No. 333 positions as shown in table 2 and appended sequence table.
Table 2
Above-mentioned PCR reactant mixture being placed in Perkin-Elmer 9700 thermal reactor (Perkin-Elmer, the Connecticut State, the U.S.), carries out ARMS-PCR, reaction condition is as follows: carry out initial denaturation 5 minutes in 95 DEG C；Carry out degeneration 1 minute in 95 DEG C, carry out bonding 2 minutes and carrying out extending 2 minutes in 72 DEG C in 58 DEG C, repeat 35 circulations；And finally extend 10 minutes in 72 DEG C.Then, PCR product is separated with 2% Eucheuma gelatinosum gel electrophoresis, and use ethidium bromide (ethidium bromide) to dye.In electrophoretic analysis, detection for TAP1-637, use the nucleic acid fragment of a length of 429 base pairs (bp) as control group nucleic acid fragment, wherein in addition to this control group nucleic acid fragment, if electrophoresis result the most additionally shows the single nucleic acid fragment of a length of 307bp, then represent this corpse or other object for laboratory examination and chemical testing TAP1 allele sequence in translate all corresponding aspartic acid (that is, Asp-637 phenogen) of amino acid whose codon of the 637th position；If electrophoresis result the most additionally shows the single nucleic acid fragment of a length of 180bp, then represent this corpse or other object for laboratory examination and chemical testing TAP1 allele sequence in translate the 637th position amino acid whose codon correspondence glycine (i.e., Gly-636 phenogen), if show the nucleic acid fragment of a length of 307bp and 180bp simultaneously, then it represents that this corpse or other object for laboratory examination and chemical testing is the shaped body (heterozygous) of Asp-637 and Gly-636).Detection as TAP1-333, use the nucleic acid fragment of a length of 533bp as control group nucleic acid fragment, wherein in addition to this control group nucleic acid fragment, if electrophoresis result the most additionally shows the single nucleic acid fragment of a length of 241bp, then represent this corpse or other object for laboratory examination and chemical testing TAP1 allele sequence in translate all corresponding isoleucine (that is, Ile-333 phenogen) of amino acid whose codon of the 333rd position；If electrophoresis result the most additionally shows the single nucleic acid fragment of a length of 352bp, then represent this corpse or other object for laboratory examination and chemical testing TAP1 allele sequence in translate all corresponding valine of amino acid whose codon of the 333rd position (i.e., Val-333 phenogen), if show the nucleic acid fragment of a length of 241bp and 352bp simultaneously, then it represents that this corpse or other object for laboratory examination and chemical testing is the shaped body of Val-333 and Ile-333).
Fig. 1 shows the results in electrophoresis of a corpse or other object for laboratory examination and chemical testing for four types, and wherein, swimming lane " M " is electrophoretic labels (marker)；Swimming lane 1 is the shaped body of Val-333 and Ile-333；Swimming lane 2 is the phenogen of Ile-333；Swimming lane 3 is the shaped body of Asp-637 and Gly-636；Swimming lane 4 is the phenogen of Asp-637.
D. specimen analyzing result and statistical analysis
The sample of above-mentioned 160 tested individualities is carried out ARMS-PCR and electrophoretic analysis in the manner described above, afterwards the data of all samples are carried out statistical analysis, use SPSS software (version 13.0, SPSS Inc., Illinois State, the U.S.), utilize leaf hereby to correct (Yates'correction) and carry out chi-square test (chi square test), the relatedness of polymorphism Yu allergic rhinitis to analyze TAP1-637 Yu TAP1-333 of TAP1 allele.Statistic is considered as having statistically significant difference with p value (p value) less than 0.05.Statistical result showed is in table 3 below and table 4.
Table 3
NS: without significant difference
Table 3 show the polymorphism analysis result of TAP1-637 Yu TAP1-333 of TAP1 allele, wherein, the codon correspondence glycine of arbitrary TAP1-637 that the codon correspondence aspartic acid of arbitrary TAP1-637 that the codon correspondence isoleucine of arbitrary TAP1-333 that the codon correspondence valine of arbitrary TAP1-333 of allele is denoted as type a, allele is denoted as type b, allele is denoted as type c, allele is denoted as type d；And the codon of arbitrary TAP1-333 of allele is that the codon correspondence aspartic acid of corresponding isoleucine and arbitrary TAP1-637 is denoted as type A, the password subsystem correspondence valine of arbitrary TAP1-333 of allele and the codon correspondence glycine of arbitrary TAP1-637 are denoted as type B, the codon correspondence valine of arbitrary TAP1-333 of allele and the codon correspondence aspartic acid of arbitrary TAP1-637 are denoted as Type C, and the codon correspondence glycine of the codon correspondence isoleucine of arbitrary TAP1-333 of allele and arbitrary TAP1-637 is denoted as type D.The result of table 3 shows, compared to control group, the tested individuality of allergic rhinitis group, the probability of the codon correspondence glycine of its TAP1-637 higher (that is, a corpse or other object for laboratory examination and chemical testing for allergic rhinitis group be type d, B or D probability higher than control group).
Table 4
Table 4 be carry out the ARMS-PCR of above-mentioned 160 tested individualities further with electrophoretic analysis result uniting whole, the relatedness of polymorphism Yu allergic rhinitis to show two TAP1-333 and two TAP1-637 of TAP1 allele.Wherein, table 4 is contained type a, b, c, d, A, B, C and D are all such as the definition of table 3；If the TAP1 allele of single tested individuality is all in type a, being then denoted as " TAP1 genotype a/a ", all the rest may be inferred for the sign of remaining genotype.
As shown in the result of table 4, the tested individuality (that is, all corresponding glycine of the codon of two TAP1-637 of TAP1 allele) of " TAP1 genotype d/d " all suffers from allergic rhinitis, and compared to control group, data p value is less than 0.05, and video data has statistically significant difference.nullIn addition，If analyzing TAP1-333 further，The tested individuality of such " TAP1 genotype d/d " can be divided into " TAP1 genotype B/B " (i.e.，The all corresponding glycine of the codon of two TAP1-637 of TAP1 allele，And all corresponding valine of the codon of TAP1-333) and " TAP1 genotype B/D " is (i.e.，The all corresponding glycine of the codon of TAP1 reciproccal basis therefore two TAP1-637，And the codon of a wherein TAP1-333 is corresponding valine，The codon of another TAP1-333 is corresponding isoleucine)，Result shows，Compared to control group，The data p value of " TAP1 genotype B/B " and " TAP1 genotype B/D " smaller than 0.05，There is statistically significant difference.
Aforesaid experimental result shows, via TAP1-637 in detection reciproccal basis (or merging detection TAP1-333 further), when all corresponding glycine of codon of two TAP1-637 of result display allele sequence (or merges detection TAP1-333 further, the codon of display TAP1-333 each corresponding valine or isoleucine) time, then can be by the highrisk populations that Chinese is allergic rhinitis of screening, if and be patients with rhinitis by the Chinese of screening itself, then this rhinitis is allergic rhinitis.
Claims (10)
1. a method for the highrisk populations of external screening allergic rhinitis, including:
(1) detection one is by antigen victory peptide transport protein matter 1 (antigen peptide transporter 1 in a corpse or other object for laboratory examination and chemical testing for screening individuality, TAP1) allele is translated the codon (codon) of the aminoacid (TAP1-637) of the 637th position, should be wherein a Chinese by screening individuality；And
(2) testing result of step (1) is judged, when the measurement result of step (1) shows all corresponding glycine (glycine) of codon of two TAP1-637 of this allele sequence, then should be the highrisk populations of allergic rhinitis by screening individuality.
2. the method for claim 1, translates the codon of the aminoacid (TAP1-333) of the 333rd position during wherein step (1) further includes the allele sequence measuring this TAP1；And step (2) includes when the measurement result of step (1) shows codon each corresponding valine (valine) or the isoleucine (isoleucine) of codon all correspondence glycine and this two TAP1-333 of two TAP1-637 of this allele sequence, then should be the highrisk populations of allergic rhinitis by screening individuality.
3. method as claimed in claim 1 or 2, wherein this Chinese is China's Mainland or TaiWan, China people.
4. method as claimed in claim 1 or 2, wherein the corpse or other object for laboratory examination and chemical testing of this step (1) is selected from following one of them: blood, blood plasma, urine, saliva, fingernail, skin and hair.
5. method as claimed in claim 4, wherein this corpse or other object for laboratory examination and chemical testing is one or both of blood and blood plasma.
6. a method for external differentiation rhinitis type, including:
(1) antigen victory peptide transport protein matter 1 (antigen peptide transporter 1 in a corpse or other object for laboratory examination and chemical testing for an individuality is detected, TAP1) translating the codon (codon) of the aminoacid (TAP1-637) of the 637th position in allele, wherein this individuality is a Chinese suffering from rhinitis；And
(2) testing result of step (1) is judged, when the measurement result of step (1) shows all corresponding glycine (glycine) of codon of two TAP1-637 of this allele sequence, and the most described rhinitis is allergic rhinitis.
7. method as claimed in claim 6, translates the codon of the aminoacid (TAP1-333) of the 333rd position during wherein step (1) further includes the allele sequence measuring this TAP1；And step (2) includes when the measurement result of step (1) shows all corresponding glycine of codon and codon each correspondence valine (valine) or the isoleucine (isoleucine) of two TAP1-333 of two TAP1-637 of this allele sequence, and the most described rhinitis is allergic rhinitis.
Method the most as claimed in claims 6 or 7, wherein this Chinese is China's Mainland or TaiWan, China people.
Method the most as claimed in claims 6 or 7, wherein the corpse or other object for laboratory examination and chemical testing of this step (1) is selected from one of: blood, blood plasma, urine, saliva, fingernail, skin and hair.
10. method as claimed in claim 9, wherein this corpse or other object for laboratory examination and chemical testing is blood and one or both in blood plasma.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW104117624 | 2015-06-01 | ||
| TW104117624A TWI545324B (en) | 2015-06-01 | 2015-06-01 | Methods for detecting or diagnosing allergic rhinitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106282326A true CN106282326A (en) | 2017-01-04 |
Family
ID=57183704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510312327.7A Withdrawn CN106282326A (en) | 2015-06-01 | 2015-06-09 | Screening or detecting method for allergic rhinitis |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN106282326A (en) |
| TW (1) | TWI545324B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101250587A (en) * | 2008-03-26 | 2008-08-27 | 上海市血液中心 | Method for identifying TAP allelomorph by SNPs combination |
| CN101525656A (en) * | 2008-03-05 | 2009-09-09 | 上海人类基因组研究中心 | Method for testing susceptibility of ankylosing spondylitis and kit |
| CN103237901A (en) * | 2010-03-01 | 2013-08-07 | 卡里斯生命科学卢森堡控股有限责任公司 | Biomarkers for theranostics |
-
2015
- 2015-06-01 TW TW104117624A patent/TWI545324B/en active
- 2015-06-09 CN CN201510312327.7A patent/CN106282326A/en not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101525656A (en) * | 2008-03-05 | 2009-09-09 | 上海人类基因组研究中心 | Method for testing susceptibility of ankylosing spondylitis and kit |
| CN101250587A (en) * | 2008-03-26 | 2008-08-27 | 上海市血液中心 | Method for identifying TAP allelomorph by SNPs combination |
| CN103237901A (en) * | 2010-03-01 | 2013-08-07 | 卡里斯生命科学卢森堡控股有限责任公司 | Biomarkers for theranostics |
Non-Patent Citations (2)
| Title |
|---|
| AWATEF ISMAIL ET AL.: "Polymorphism in transporter antigen peptides gene (TAP1) associated with atopy in Tunisians", 《J ALLERGY CLIN IMMUNOL》 * |
| KYUNG RAE KIM ET AL.: "TAP1 and TAP2 Gene Polymorphisms in Korean Patients with Allergic Rhinitis", 《JOURNAL OF KOREAN MEDICAL SCIENCE》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| TW201643432A (en) | 2016-12-16 |
| TWI545324B (en) | 2016-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014533949A5 (en) | ||
| CN105143467A (en) | Methods for predicting risk of interstitial pneumonia | |
| CN107760779B (en) | Mutant BMP9 gene related to pulmonary hypertension and application thereof | |
| CN110093413A (en) | Detect the primer sets and kit of beta Thalassemia | |
| CN105567861B (en) | Purposes of the IFI27 as diagnosis of coronary heart disease marker | |
| CN103571847A (en) | FOXC1 gene mutant and its application | |
| CN111647673A (en) | Application of microbial flora in acute pancreatitis | |
| US10939868B2 (en) | Method of predicting rapid progression of fibrosis and therapy and reagents therefor | |
| CN104450727A (en) | Pathogenic gene for X-linked hypophosphatemic rickets as well as protein encoded by pathogenic gene and application of pathogenic gene | |
| DK2931920T3 (en) | BIOMARKERS FOR INFLAMMATORY ASTMPHENotypes AND TREATMENT RESPONSE | |
| US20140221235A1 (en) | Biomarker algorithm for determining the time of stroke symptom onset and method | |
| CN112662754B (en) | Methods of using compositions for predicting the probability of occurrence of small ear deformities | |
| CN106282326A (en) | Screening or detecting method for allergic rhinitis | |
| CN108034714A (en) | Application of the ARHGAP26 genes in Parkinson's diagnostic tool is prepared | |
| CN107904304B (en) | Purposes of the DNASE2 as parkinsonism diagnosis marker | |
| WO2012006534A4 (en) | Methods, compositions and kits for diagnosing and treating alzheimer's disease using mitochondrial co3 gene mutations | |
| JP2022520427A (en) | Saliva biomarker for brain injury | |
| CN113265409B (en) | TIMM21 mutant gene, primer, kit and method for detecting same and application thereof | |
| RU2693471C1 (en) | Diagnostic technique for early manifestations of respiratory allergosis in children in conditions of excessive contamination with aluminum | |
| ES2783698B2 (en) | CELIAC DISEASE DIAGNOSIS METHOD BASED ON THE EXPRESSION LEVEL OF THE UBE2L3 GENE | |
| CN112226501B (en) | Intestinal flora marker for myasthenia gravis and application thereof | |
| CN108220420A (en) | A kind of gene marker for being used to diagnose Parkinson | |
| US20240254555A1 (en) | Heart Transplant Rejection mRNA prognostic and diagnostic Biomarkers | |
| CN114774552A (en) | Diagnosis marker and diagnosis reagent for nevoid basal cell carcinoma syndrome and application | |
| CN106834491B (en) | Breast cancer prognosis-related gene mutation detection kit and its application method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170104 |